Dr. Howard Berman is currently the Founder and Executive Chairman of Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical stage biotechnology company that is developing disease modifying therapies for neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease), Frontotemporal Dementia, Parkinson’s Disease, and Alzheimer’s Disease. He is the winner of the 2024 PharmaVoice 100 winner as a Biotech Pathfinder (recognizing the most inspiring people in the life sciences industry), 2024 Scrip Awards finalist for the category Executive of the Year for Clinical-Stage Companies, 2024 Finalist-Fierce Innovation Awards, and 2024 Finalist in Houston Innovation Map Awards. He is driven and defined by four characteristics: Grit, Resilience, Perseverance, and “Under-promising and Over- delivering”.

Dr. Berman graduated with Highest Honors from the University of Michigan with a Bachelor in Biology, and from Weill Cornell Medical School with a Masters and Ph.D. in Neuroscience and Pharmacology. Dr. Berman has over 20 years of entrepreneurial, technology transfer, and industry experience working at the interplay of science and business.